A groundbreaking vaccine offers hope for preventing cancer in individuals with Lynch syndrome, a genetic condition that casts a dark shadow over families. This story is a testament to the power of medical innovation and the resilience of those affected.
Cancer's Legacy in a Dutch-Canadian Family
The Heyink family, with its Dutch roots in Canada, has been haunted by cancer for generations. Geertruida Heyink, Kevin's maternal grandmother, succumbed to what was believed to be stomach cancer at just 36 years old. Tragically, seven of her eight siblings also died from cancer.
This grim pattern continued with Geertruida's children, including Kevin's father, John Heyink. John managed to see his children grow up only because he underwent a life-saving colon removal in the 1980s, preventing the spread of cancer.
Lynch Syndrome: A Genetic Threat
Kevin, a 48-year-old police officer near Hamilton, Ontario, carries the weight of Lynch syndrome, an inherited condition that significantly increases the risk of colon, endometrial, and stomach cancers, among others. His oldest brother passed away from cancer at the same age Kevin is now, and two of his younger brothers have already battled the disease.
Despite these challenges, Kevin remains cancer-free. He attributes this to his participation in a clinical trial for a promising vaccine, Nous-209, designed to prevent cancer in those with Lynch syndrome.
A Ray of Hope
"Before, it was a matter of when, not if, I would get cancer," Kevin shared. "Now, there's a real possibility that cancer might never touch me."
Kevin is one of 45 participants in the early-phase trial of Nous-209, a vaccine that teaches the immune system to identify and attack specific proteins found on precancerous cells in Lynch syndrome patients.
Lynch syndrome is believed to affect at least three out of every 300 Canadians, and carriers have a 50-50 chance of passing it on to their children.
Early Signs of Success
While it's too early to confirm the vaccine's effectiveness in preventing cancer, the initial trial results, published in Nature Medicine, are promising. The small-scale trial aimed to test the vaccine's safety and its ability to trigger the desired immune response in healthy participants with Lynch syndrome.
Dr. Raymond Kim, medical director of cancer early detection and the Bhalwani Familial Cancer Clinic at the Princess Margaret Cancer Centre in Toronto, commented on the findings. "The fact that the vaccine elicited an immune response specific to peptides frequently seen in Lynch syndrome cancers is quite promising. They're on the right track."
A Milestone in Cancer Prevention
If Nous-209 or another candidate vaccine proves successful in preventing cancer in Lynch patients, it would be a significant milestone. There are currently no approved vaccines to prevent hereditary cancers, and most cancer vaccines in development are therapeutic, designed to treat or prevent recurrence in diagnosed patients.
Existing vaccines that prevent cancer do so indirectly, by preventing infections with the human papillomavirus (HPV) and hepatitis B viruses, which cause cervical and liver cancer, respectively.
The Biology of Lynch Syndrome
Dr. Eduardo Vilar-Sanchez, leader of the Nous-209 trial and professor at MD Anderson Cancer Center, explained that the biology of Lynch syndrome makes it an ideal target for a vaccine. The syndrome is caused by an inherited mutation in one of four mismatch-repair genes, which are responsible for fixing errors in DNA sequencing that occur during cell division.
When the mismatch-repair system fails, mistakes accumulate, leading to the production of frameshift peptides, which are commonly found on Lynch-induced tumours. A vaccine could potentially train the immune system to recognize and eliminate these frameshift peptides and the cancerous or precancerous cells they inhabit.
Early Trial Results
The early-phase study found that the Nous-209 vaccine, developed with an inactivated adenovirus by the Swiss biotech company Nouscom, was safe and induced an immune response in all participants. However, the strength of the response varied.
The most exciting finding was the outcome of participants' colonoscopies one year after receiving the vaccine. Precancerous lesions were less common in those who mounted a strong immune response to the vaccine, as determined by blood tests.
"We didn't see any advanced polyps or lesions in the vaccinated population," Dr. Vilar-Sanchez said.
A Personal Journey
Kevin Heyink's colonoscopies have been clear since he received his first dose of Nous-209 in Houston. Previously, he had precancerous cells or lesions removed during annual colonoscopies, which began in his 20s after genetic testing confirmed his Lynch syndrome status.
Kevin was surprised when a Canadian doctor casually mentioned that his latest scope showed no concerns. "He just said it so nonchalantly," Kevin recalled. "I had to remind him how incredible this was."
Kevin, a father of four, raised funds through a GoFundMe campaign to cover the costs of travelling to and from Houston for the trial.
The Impact of Lynch Syndrome
Kevin's father, who passed away from cancer in 2009 at 65, was the first in the family to discover he had hereditary nonpolyposis colorectal cancer in the 1990s. The syndrome was later named after Henry Lynch, a renowned U.S. physician who studied the genetics of inherited cancers.
Kevin's experiences mirror those of his father, who closely followed Lynch syndrome research. The family's experiences highlight the unpredictable nature of Lynch syndrome, with varying outcomes among siblings.
A Brother's Battle
Nathan, Kevin's younger brother, has Lynch syndrome and has survived stomach and liver cancer. He is now 40 and a father of six, facing the additional challenge of raising children who may carry the syndrome.
Nathan shared that one of his sons was particularly close to their late uncle, Dave, who passed away from adrenal gland cancer at 48. "It was hard on him, especially when I was sick too. He worried it was contagious and that he would get it. It's a tough situation to navigate."
A Catalyst for Action
Dave's death served as a catalyst for Kevin to find and join the vaccine trial. "After Dave passed, I felt a responsibility towards his kids and mine."
The Nous-209 vaccine trial offers a glimmer of hope for those with Lynch syndrome, providing a potential tool to prevent cancer and break the cycle that has plagued families like the Heyinks for generations.
